8-K: Cryoport Q2 Revenue Jumps 14%; DHL Deal Boosts Capital

Cryoport, Inc. reported strong second quarter 2025 financial results with a 14% year-over-year revenue increase and a significant capital infusion from the CRYOPDP divestiture and DHL partnership.

Summary

• Total revenue from continuing operations for Q2 2025 increased 14% year-over-year to $45.5 million.
• Life Sciences Services revenue grew 21% year-over-year to $24.4 million, accounting for 54% of total revenue.
• Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million.
• BioStorage/BioServices revenue rose 28% year-over-year to $4.5 million.
• Life Sciences Products revenue grew 8% year-over-year to $21.1 million.
• Gross margin from continuing operations improved to 47.0% for Q2 2025, up from 44.5% in Q2 2024.
• Net income for Q2 2025 was $105.2 million, primarily driven by a $117.4 million gain (net of taxes) from the sale of the CRYOPDP business.
• Adjusted EBITDA was a negative $0.9 million for Q2 2025, a significant improvement from negative $5.6 million in Q2 2024.
• As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $426.0 million.
• Supported 728 global clinical trials as of June 30, 2025, a net increase of 44 trials year-over-year, with 82 in Phase 3.
• Reaffirmed full-year 2025 revenue guidance of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year.

Sentiment

Score: 9

Explanation: The filing indicates very strong positive sentiment due to robust revenue growth across key segments, significant improvement in gross margin and adjusted EBITDA, a major strategic partnership with DHL that infused substantial capital, and positive regulatory developments for supported therapies. The reaffirmation of guidance and share repurchase program further bolster confidence.

Positives

• Strong double-digit revenue growth across all Life Sciences Services streams, including 21% for Life Sciences Services overall, 20% for BioLogistics Solutions, and 28% for BioStorage/BioServices.
• Significant 33% year-over-year increase in revenue from commercial cell and gene therapies, indicating strong market adoption.
• Improved gross margin from continuing operations, reaching 47.0% in Q2 2025, reflecting progress towards profitability.
• Substantial reduction in Adjusted EBITDA loss, moving from negative $5.6 million in Q2 2024 to negative $0.9 million in Q2 2025.
• Successful divestiture of CRYOPDP and strategic partnership with DHL Group, providing a strong capital infusion and enhancing global biologistics capabilities, particularly in EMEA and APAC.
• Increased support for global clinical trials, with a net increase of 44 trials year-over-year, demonstrating continued pipeline growth.
• FDA approval for Abeona Therapeutics' ZEVASKYNTM, a Cryoport-supported cell therapy.
• FDA's removal of REMS requirements for approved BCMAand CD19-directed autologous CAR-T cell immunotherapies, which is expected to increase patient access and accelerate commercial scaling for supported therapies like Carvykti, Yescarta, Tecartus, and Breyanzi.
• Reaffirmation of full-year 2025 revenue guidance, signaling confidence in continued growth.
• Repurchased 1 million shares of common stock since the beginning of Q2 2025, demonstrating commitment to shareholder value.

Negatives

• Despite significant one-time gain, the company reported a net loss from continuing operations of $12.2 million for Q2 2025 (excluding the gain on sale of CRYOPDP).
• Adjusted EBITDA remains negative, indicating the company is not yet consistently profitable on an operational basis.

Risks

• The company's actual results could differ materially from forward-looking statements due to changing economic and geopolitical conditions.
• Potential impact from supply chain constraints and inflationary pressures.
• Risks associated with tariffs and other trade restrictions.
• Effects of foreign currency fluctuations on financial results.
• Variations in the company's cash flow.
• Market acceptance risks for new products and services.
• Technical development risks related to new offerings.
• Any disruption resulting from the DHL Transaction may adversely affect businesses and business relationships, including with employees and suppliers.

Future Outlook

The company reaffirmed its full-year 2025 revenue guidance, expecting total revenue from continuing operations to be in the range of $165.0 million to $172.0 million, representing 5% to 10% year-over-year growth. Management anticipates up to an additional twenty application filings, one new therapy approval, and three additional approvals for label/geographic expansions during the remainder of 2025. The Global Supply Chain Center in Paris is expected to launch in late 2025, and the Santa Ana, California center in the second half of 2026.

Management Comments

• "Cryoport delivered strong, double-digit growth across all revenue streams within Life Sciences Services in the second quarter, increasing 21% year-over-year and accounting for 54% of total revenue from continuing operations."
• "This growth continues to be fueled by the increasing development and adoption of cell & gene therapies, a positive trend we believe will continue for years to come."
• "The 14% year-over-year increase in total revenue from continuing operations, combined with our planned pathway to profitability, contributed to an increase in gross margin and a meaningful improvement in our adjusted EBITDA."
• "With strong execution across all business units, we are reaffirming our full-year 2025 revenue guidance as we move towards our goal of sustainable, long-term profitability."
• "This transaction with DHL delivered both a strong infusion of capital, a substantial return on investment, and strengthened our global biologistics capabilities and effectiveness."
• "By leveraging DHLs competencies, scale, and reach in APAC and EMEA, we believe we will be increasingly well positioned to expand our Life Sciences Services business and deepen our leadership in the developing global regenerative medicine market."
• "In summary, the second quarter was marked by strong revenue growth, improved profitability, and the execution of a transformative partnership strategy. We are entering the second half of the year with strong momentum and a clear focus on driving long-term shareholder value."

Industry Context

Cryoport operates at the forefront of the temperature-controlled supply chain for the life sciences, a critical and growing segment driven by the rapid development and commercialization of cell and gene therapies. The company's strong double-digit growth in Life Sciences Services, particularly in commercial cell and gene therapy support, aligns with the accelerating demand for specialized logistics and storage solutions in this innovative sector. The strategic partnership with DHL Group positions Cryoport to leverage DHL's extensive global network, particularly in the APAC and EMEA regions, which are key growth markets for regenerative medicine. The FDA's removal of REMS requirements for certain CAR-T cell immunotherapies is a significant positive industry trend, reducing regulatory hurdles and potentially expanding patient access, directly benefiting Cryoport's supported therapies and accelerating commercial scaling.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. It highlights Cryoport's position as a 'leading global provider' and its aim to 'deepen leadership in the developing global regenerative medicine market' but lacks explicit comparative data points.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to strong financial performance, strategic growth initiatives, significant capital infusion from divestiture, and share repurchase program, all contributing to potential long-term shareholder value.
• **Customers**: Positive impact through enhanced global biologistics capabilities via the DHL partnership, new service offerings like Cryoshuttle in Tokyo, and new product launches (MVE vapor shippers, High-Efficiency 800C system), improving service reliability and access.
• **Employees**: Potential for disruption related to the DHL transaction is noted as a risk, but the overall growth trajectory and strategic focus on high-value services could offer long-term stability and opportunities within the continuing operations.
• **Suppliers**: Potential for disruption related to the DHL transaction is noted as a risk, which could impact supplier relationships.
• **Creditors**: Positive impact due to a significantly strengthened cash position and improved financial health, reducing credit risk.

Next Steps

• Continue plans to complete Global Supply Chain Center in Paris, France, with expected launch in late 2025.
• Continue plans to complete Global Supply Chain Center in Santa Ana, California, with expected launch in the second half of 2026.
• Anticipate up to an additional twenty application filings for therapies during the remainder of 2025.
• Anticipate one new therapy approval during the remainder of 2025.
• Anticipate an additional three approvals for label/geographic expansions during the remainder of 2025.
• File the Quarterly Report on Form 10-Q for the three months ended June 30, 2025, with the SEC on August 7, 2025.

Key Dates

Recommendation

The filing presents a compelling case for a strong buy. Cryoport demonstrated robust revenue growth across its core Life Sciences segments, particularly in the high-growth cell and gene therapy space. The significant improvement in gross margin and adjusted EBITDA indicates a clear path towards profitability. The strategic divestiture of CRYOPDP, coupled with the DHL partnership, not only provided a substantial capital infusion but also strategically positions the company for enhanced global reach and focus on its high-value services. The reaffirmation of full-year guidance and ongoing share repurchase program further underscore management's confidence and commitment to shareholder returns. These factors, combined with positive industry tailwinds like the FDA's regulatory adjustments, suggest strong future performance and market leadership.

Keywords

Cryoport, Life Sciences, Temperature-Controlled Supply Chain, Cell and Gene Therapy, Biologistics, Biostorage, Cryogenic Systems, Biopharmaceutical, Clinical Trials, DHL Group, Regenerative Medicine, Financial Results